INDEX

A

A Common Sense Approach to Common or Usual Names, if Any There Be. June, p. 284.

Abbreviated New Drug Applications
Paper NDAs and ANDAs for Post-1962 Drugs—The Pioneer Manufacturer's View. Mar., p. 129.

Advertising
FTC Regulation of OTC Drug and Cosmetics Advertising. Mar., p. 100.
Phase I of the FTC's Food Advertising Rule: Its Scope and Impact. May, p. 220.

Agency Lawyer
The Role of the Lawyer in Agency Decision-Making. Oct., p. 510.

Agriculture Department
Improving the Labeling Process. May, p. 258.

Allera, Edward John—FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

Announcement: Change of Publisher for the Food Drug Cosmetic Law Journal. Oct., p. 508.

The Best Proof of Safety for Food Additives and New Animal Drugs. Apr., p. 185.

B

Bewley, Peter D.—How the IRBs and GLPs Affect Clinical Data Submissions. Aug., p. 447.

Bewley, Peter D.—The Role of Corporate Management During a Device Inspection. Oct., p. 536.

Blood and Blood Products: A Five Year Challenge. Jan., p. 27.

Blood Products
A Five Year Challenge. Jan., p. 27.

Bureau of Biologics
Blood and Blood Products: A Five Year Challenge. Jan., p. 27.

Bureau of Drugs
From Investigation to Marketplace: Moving Drugs Through the System. Apr., p. 166.

C

Canada
Food Safety and Regulations—A Canadian Perspective. Mar., p. 120.

Change of Publisher
Announcement: Change of Publisher for the Food Drug Cosmetic Law Journal. Oct., p. 508.

Chemical Residues
Food Safety and Chemical Residues. Jan., p. 33.

Compliance Programs
FDA's Sterilization Compliance Program. Sept., p. 460.
FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

Condon, William J.—Product Liability—1980. Apr., p. 175.

Controlled Substances
Professional Sampling of Controlled Substances. July, p. 363.

Cooper, Richard M.—Scientists and Lawyers in the Legal Process. Jan., p. 9.

Corporate Management
The Role of Corporate Management During a Device Inspection. Oct., p. 536.

INDEX

A

A Common Sense Approach to Common or Usual Names, if Any There Be. June, p. 284.

Abbreviated New Drug Applications
Paper NDAs and ANDAs for Post-1962 Drugs—The Pioneer Manufacturer's View. Mar., p. 129.

Advertising
FTC Regulation of OTC Drug and Cosmetics Advertising. Mar., p. 100.
Phase I of the FTC's Food Advertising Rule: Its Scope and Impact. May, p. 220.

Agency Lawyer
The Role of the Lawyer in Agency Decision-Making. Oct., p. 510.

Agriculture Department
Improving the Labeling Process. May, p. 258.

Allera, Edward John—FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

Announcement: Change of Publisher for the Food Drug Cosmetic Law Journal. Oct., p. 508.

The Best Proof of Safety for Food Additives and New Animal Drugs. Apr., p. 185.

B

Bewley, Peter D.—How the IRBs and GLPs Affect Clinical Data Submissions. Aug., p. 447.

Bewley, Peter D.—The Role of Corporate Management During a Device Inspection. Oct., p. 536.

Blood and Blood Products: A Five Year Challenge. Jan., p. 27.

Blood Products
A Five Year Challenge. Jan., p. 27.

Bureau of Biologics
Blood and Blood Products: A Five Year Challenge. Jan., p. 27.

Bureau of Drugs
From Investigation to Marketplace: Moving Drugs Through the System. Apr., p. 166.

C

Canada
Food Safety and Regulations—A Canadian Perspective. Mar., p. 120.

Change of Publisher
Announcement: Change of Publisher for the Food Drug Cosmetic Law Journal. Oct., p. 508.

Chemical Residues
Food Safety and Chemical Residues. Jan., p. 33.

Compliance Programs
FDA's Sterilization Compliance Program. Sept., p. 460.
FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

Condon, William J.—Product Liability—1980. Apr., p. 175.

Controlled Substances
Professional Sampling of Controlled Substances. July, p. 363.

Cooper, Richard M.—Scientists and Lawyers in the Legal Process. Jan., p. 9.

Corporate Management
The Role of Corporate Management During a Device Inspection. Oct., p. 536.

Cosmetic Regulatory Update—1980. Feb., p. 90.

Cosmetics
Cosmetic Regulatory Update—1980. Feb., p. 90.
Risk Assessment and Cosmetic Regulation: The Outlook. Apr., p. 203.

Court Cases
Perspectives on the FDA Status of Drug Products Manufactured by the Recombinant DNA Technique. Oct., p. 517.

Criminal Liability
Criminal Liability Under the FDC Act—the Large Corporation Perspective. June, p. 314.

Criminal Liability Under the Federal Food, Drug, and Cosmetic Act—the Large Corporation Perspective. June, p. 314.

Crout, J. Richard—The Drug Regulatory System: Reflections and Predictions. Mar., p. 106.

Crown, Michele F.—Improving the Labeling Process. May, p. 258.

Cyclic Review
Cyclic Review—Looking Backward on Looking Forward? Apr., p. 156.

Cyclic Review—Looking Backward or Looking Forward? Apr., p. 156.

D

Davids, James A.—DEA Administrative Inspections: Authority and Practical Applications. May, p. 229.

DEA Administrative Inspections: Authority and Practical Applications. May, p. 229.

Degnan, Frederick H.—The Best Proof of Safety for Food Additives and New Animal Drugs. Apr., p. 185.

Degnan, Frederick H.—The Role of the Lawyer in Agency Decision-Making. Oct., p. 510.

Device Act
Optical Products—Doing Business Today. Feb., p. 52.

Dietary Recommendations
Regulatory Implementation of Dietary Recommendations. Feb., p. 66.

Donohue, Dennis M.—Blood and Blood Products: A Five Year Challenge. Jan., p. 27.

Drug Enforcement Administration
Administrative Inspections: Authority and Practical Applications. May, p. 229.

Drug Liability
The New California "Market Share" Theory in Drug Liability Cases. Jan., p. 39.

Drug Regulation
The Drug Regulatory System: Reflections and Predictions. Mar., p. 106.
From Investigation to Marketplace: Moving Drugs Through the System. Apr., p. 166.
Outline of the History of U. S. Drug Regulation and Labeling. Aug., p. 420.

The Drug Regulatory System: Reflections and Predictions. Mar., p. 106.

E

EEC Directives on the Approximation of Member States' Legislation Relating to Foodstuffs. Oct., p. 543.

Eiermann, Heinz J.—Cosmetic Regulatory Update—1980. Feb., p. 90.

Engel, Ronald E.—Food Safety and Chemical Residues. Jan., p. 33.

European Economic Community
EEC Directives on the Approximation of Member States' Legislation Relating to Foodstuffs. Oct., p. 543.

Everbach, O. George—Optical Products—Doing Business Today. Feb., p. 52.

Expert Witnesses
Presenting and Challenging Expert Witnesses in Cases Involving the New Drug—Old Drug Issue. July, p. 372.

F

FDA

The Future of the FDA Under a New Administration. Feb., p. 60.

Inspection: What You Need to Know to Protect Your Company. May, p. 245.

Major Regulatory Challenges. Nov., p. 565.

The Role of the Lawyer in Agency Decision-Making. Oct., p. 510.

An FDA Inspection: Preparing for the Inevitable. Dec., p. 641.

The FDA Inspection: What You Need to Know to Protect Your Company. May, p. 245.

FDA Inspections and Criminal Responsibility. Sept., p. 469.

FDA Investigator

FDA Investigator: "From His Office to Yours." Sept., p. 486.

FDA Investigator: "From His Office to Yours." Sept., p. 486.

FDA List

Approved Drug Products and Generic Drug Substitution. Nov., p. 556.

FDA Regulations and Product Liability. Sept., p. 478.

FDA's Sterilization Compliance Program. Sept., p. 460.

FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

FDC Act

Criminal Liability—The Large Corporation Perspective. June, p. 314.

FDA Inspections and Criminal Responsibility. Sept., p. 469.

Protection of the American Consumer: The Muckrakers and the Enactment of the First Federal Food and Drug Law in the United States. Dec., p. 647.

Does Self-Medication Have a Role in Our Society? Dec., p. 604.

Use of Summary Judgment by the FDA to Avoid Formal Adjudication: In the Public Interest? Aug., p. 396.

Federal Trade Commission

FTC Regulation of OTC Drug and Cosmetics Advertising. Mar., p. 100.

Phase I of the FTC's Food Advertising Rule: Its Scope and Impact. May, p. 220.

Feinberg, Marc M.—FDA Investigator: "From His Office to Yours." Sept., p. 486.

Food Additives

The Best Proof of Safety for Food Additives and New Animal Drugs. Apr., p. 185.

Cyclic Review—Looking Backward or Looking Forward? Apr., p. 156.

Food and Drug Recalls

Mandatory Food and Drug Recalls: An Analysis of a Developing FDA Enforcement Tool. Dec., p. 669.

Food Labeling

A Common Sense Approach to Common or Usual Names, if Any There Be. June, p. 284.

Food Laws

Food Laws and Regulation: The Impact on Food Research. June, p. 293.

Food Laws and Regulation: The Impact on Food Research. June, p. 293.

Food Regulations

Food Laws and Regulation: The Impact on Food Research. June, p. 293.

The Product Labeling Controversy. July, p. 381.

Food Research

Food Laws and Regulation: The Impact on Food Research. June, p. 293.

Food Safety

Food Safety and Chemical Residues. Jan., p. 33.

Food Safety and Regulations—A Canadian Perspective. Mar., p. 120.

Food Safety and Chemical Residues. Jan., p. 33.

Food Safety and Regulations—A Canadian Perspective. Mar., p. 120.

Foreign Data
EEC Directives on the Approximation of Member States' Legislation Relating to Foodstuffs. Oct., p. 543.
Use of Foreign Data in a New Drug Application. June, p. 340.

Frey, LaRene Oliver—Professional Sampling of Controlled Substances. July, p. 363.

From Investigation to Marketplace: Moving Drugs Through the System. Apr., p. 166.

FTC Regulation of OTC Drug and Cosmetics Advertising. Mar., p. 100.

The Future of the FDA Under a New Administration. Feb., p. 60.

G

Generic Drug Substitution and the FDA List of Approved Drug Products. Nov., p. 556.

Generic Drugs
Substitution and the FDA List of Approved Drug Products. Nov., p. 556.

Gerard, Alain—EEC Directives on the Approximation of Member States' Legislation Relating to Foodstuffs. Oct., p. 543.

Good Laboratory Practices
How the IRBs and GLPs Affect Clinical Data Submissions. Aug., p. 447.

Goyan, Jere E.—The Future of the FDA Under a New Administration. Feb., p. 60.

Guidelines
FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

Guttenberger, Ann E.—Use of Summary Judgment by the FDA to Avoid Formal Adjudication: In the Public Interest? Aug., p. 396.

H

Halperin, Jerome A.—From Investigation to Marketplace: Moving Drugs Through the System. Apr., p. 166.

Hansen, Arthur W.—An FDA Inspection: Preparing for the Inevitable. Dec., p. 641.

Harper, Blake M.—Mandatory Food and Drug Recalls: An Analysis of a Developing FDA Enforcement Tool. Dec., p. 669.

Hayes, Jr., Arthur Hull.—Major Regulatory Challenges Confronting the FDA. Nov., p. 565.

Health Care Technology: The Impact of Regulation. Aug., p. 442.

Henteleff, Thomas—OTC—A Privileged Class? June, p. 332.

How the IRBs and GLPs Affect Clinical Data Submissions. Aug., p. 447.

Hutt, Peter Barton—Regulatory Implementation of Dietary Recommendations. Feb., p. 66.

Hyman, Paul M.—Paper NDA Update. June, p. 303.

I

The Impact of New Technology on Regulation by the FDA: Recombinant DNA Technology. July, p. 348.

Implantable Medical Devices and Products Liability. Dec., p. 622.

Imported Foods
Problems in the Control of Pesticide Residue on Imported Foods. Nov., p. 573.

Improving the Labeling Process. May, p. 258.

IND/NDA
The IND/NDA Rewrite: Rewritten. July, p. 354.

The IND/NDA Rewrite: Rewritten. July, p. 354.

Inspection Policy. Sept., p. 493.

Inspections
DEA Administrative Inspections: Authority and Practical Applications. May, p. 229.

An FDA Inspection: Preparing for the Inevitable. Dec., p. 641.

FDA Inspections and Criminal Responsibility. Sept., p. 469.

FDA Investigator: "From His Office to Yours." Sept., p. 486.

Inspection Policy. Sept., p. 493.

The Role of Corporate Management During a Device Inspection. Oct., p. 536.

What You Need to Know to Protect Your Company. May, p. 245.

Institutional Review Boards
How the IRBs and GLPs Affect Clinical Data Submissions. Aug., p. 447.

J

Janssen, Wallace F.—Outline of the History of U. S. Drug Regulation and Labeling. Aug., p. 420.

K

Kahan, Jonathan S.—Criminal Liability Under the Federal Food, Drug, and Cosmetic Act—The Large Corporation Perspective. June, p. 314.

Korwek, Edward L.—Perspectives on the FDA Status of Drug Products Manufactured by the Recombinant DNA Technique. Oct., p. 517.

L

Labeling
A Common Sense Approach to Common or Usual Names, if Any There Be. June, p. 284.

Improving the Labeling Process. May, p. 258.

Outline of the History of U. S. Drug Regulation and Labeling. Aug., p. 420.

The Product Labeling Controversy. July, p. 381.

Labuza, Theodore P.—Food Laws and Regulation: The Impact on Food Research. June, p. 293.

Land, Stuart J.—The New California "Market Share" Theory in Drug Liability Cases. Jan., p. 39.

Law
Litigating an "Old Drug"/"New Drug" Case: Victory Lies Outside the Courtroom. Apr., p. 191.

Medical Devices—Intent and Implementation. Jan., p. 4.

Product Liability—1980. Apr., p. 175.

Scientists and Lawyers in the Legal Process. Jan., p. 9.

Levitt, Joseph A.—FDA Inspections and Criminal Responsibility. Sept., p. 469.

Litigating an "Old Drug"/"New Drug" Case: Victory Lies Outside the Courtroom. Apr., p. 191.

Litman, Donald Saunders—Protection of the American Consumer: The Muckrakers and the Enactment of the First Federal Food and Drug Law in the United States. Dec., p. 647.

Litman, Richard Curtis—Protection of the American Consumer: The Muckrakers and the Enactment of the First Federal Food and Drug Law in the United States. Dec., p. 647.

M

Major Regulatory Challenges Confronting the FDA. Nov., p. 565.

Market Share
The New California "Market Share" Theory in Drug Liability Cases. Jan., p. 39.

Mandatory Food and Drug Recalls: An Analysis of a Developing FDA Enforcement Tool. Dec., p. 669.

McNamara, Stephen H.—The FDA Inspection: What You Need to Know to Protect Your Company. May, p. 245.

Medical Device Law—Intent and Implementation. Jan., p. 4.

Medical Devices
Health Care Technology: The Impact of Regulation. Aug., p. 442.
Implantable Medical Devices and Products Liability. Dec., p. 622.
Medical Device Law—Intent and Implementation. Jan., p. 4.
The Role of Corporate Management During a Device Inspection. Oct., p. 536.

Mehlman, Maxwell J.—The New California "Market Share" Theory in Drug Liability Cases. Jan., p. 39.

Miller, Henry I.—The Impact of New Technology on Regulation by the FDA: Recombinant DNA Technology. July, p. 348.

Miller, Paul S.—The IND/NDA Rewrite: Rewritten. July, p. 354.

Muckrakers
Protection of the American Consumer: The Muckrakers and the Enactment of the First Federal Food and Drug Law in the United States. Dec., p. 647.

N

New Animal Drugs
The Best Proof of Safety for Food Additives and New Animal Drugs. Apr., p. 185.

The New California "Market Share" Theory in Drug Liability Cases. Jan., p. 39.

New Drug Applications
The IND/NDA Rewrite: Rewritten. July, p. 354.
Paper NDA Update. June, p. 303.
Paper NDAs and ANDAs for Post-1962 Drugs—The Pioneer Manufacturer's View. Mar., p. 129.
Use of Foreign Data in a New Drug Application. June, p. 340.

New Drugs
OTC—a Privileged Class? June, p. 332.
Perspectives on the FDA Status of Drug Products Manufactured by the Recombinant DNA Technique. Oct., p. 517.

Nicholas, Jeffrey H.—Problems in the Control of Pesticide Residue on Imported Foods. Nov., p. 573.

Notices
FDA's Use of Guidelines, Notices of Proposed Rulemaking, and Compliance Policies as De Facto Rules: An Abuse of Discretion. May, p. 270.

Novitch, Mark—Health Care Technology: The Impact of Regulation. Aug., p. 442.

O

Old Drugs/New Drugs
Litigating an "Old Drug"/"New Drug" Case: Victory Lies Outside the Courtroom. Apr., p. 191.
Presenting and Challenging Expert Witnesses in Cases Involving the New Drug—Old Drug Issue. July, p. 372.

Optical Products
Doing Business Today. Feb., p. 52.

Optical Products—Doing Business Today. Feb., p. 52.

Orlans, Melvin H.—FTC Regulation of OTC Drug and Cosmetics Advertising. Mar., p. 100.

Orlans, Melvin H.—Phase I of the FTC's Food Advertising Rule: Its Scope and Impact. May, p. 220.

OTC—a Privileged Class? June, p. 332.

OTC Drugs
OTC—a Privileged Class? June, p. 332.

Outline of the History of U. S. Drug Regulation and Labeling. Aug., p. 420.

P

Paper NDA
Paper NDA Update. June, p. 303.

Paper NDA Update. June, p. 303.

Paper NDAs and ANDAs for Post-1962 Drugs—The Pioneer Manufacturer's View. Mar., p. 129.

Perez, Jerry—The Product Labeling Controversy. July, p. 381.

Perspectives on the FDA Status of Drug Products Manufactured by the Recombinant DNA Technique. Oct., p. 517.

Pesticides
Problems in the Control of Pesticide Residue on Imported Foods. Nov., p. 573.

Phase I of the FTC's Food Advertising Rule: Its Scope and Impact. May, p. 220.

Posner, Kenneth—Implantable Medical Devices and Products Liability. Dec., p. 622.

Presenting and Challenging Expert Witnesses in Cases Involving the New Drug—Old Drug Issue. July, p. 372.

Problems in the Control of Pesticide Residue on Imported Foods. Nov., p. 573.

Product Liability
FDA Regulations and Product Liability. Sept., p. 478.
Implantable Medical Devices and Products Liability. Dec., p. 622.
Product Liability—1980. Apr., p. 175.

Product Liability—1980. Apr., p. 175.

Professional Sampling
Professional Sampling of Controlled Substances. July, p. 363.

Professional Sampling of Controlled Substances. July, p. 363.

Protection of the American Consumer: The Muckrakers and the Enactment of the First Federal Food and Drug Law in the United States. Dec., p. 647.

Publisher
Announcement: Change of Publisher for the Food Drug Cosmetic Law Journal. Oct., p. 508.

R

Read, Ron O.—Food Safety and Regulations—A Canadian Perspective. Mar., p. 120.

Reagan Administration
The Future of the FDA Under a New Administration. Feb., p. 60.

Recalls
Mandatory Food and Drug Recalls: An Analysis of a Developing FDA Enforcement Tool. Dec., p. 669.

Recombinant DNA
The Impact of New Technology on Regulation by the FDA. July, p. 348.
Perspectives on the FDA Status of Drug Products Manufactured by the Recombinant DNA Technique. Oct., p. 517.

Regulations
Cosmetic Regulatory Update—1980. Feb., p. 90.
The Drug Regulatory System: Reflections and Predictions. Mar., p. 106.
FDA Regulations and Product Liability. Sept., p. 478.
Health Care Technology: The Impact of Regulation. Aug., p. 442.
The Impact of New Technology on Regulation by the FDA: Recombinant DNA Technology. July, p. 348.
Major Regulatory Challenges Confronting the FDA. Nov., p. 565.
Outline of the History of U. S. Drug Regulation and Labeling. Aug., p. 420.
Regulatory Implementation of Dietary Recommendations. Feb., p. 66.

Regulatory Implementation of Dietary Recommendations. Feb., p. 66.

Risk Assessment
Risk Assessment and Cosmetic Regulation: The Outlook. Apr., p. 203.

Risk Assessment and Cosmetic Regulation: The Outlook. Apr., p. 203.

Rogart, Mark Edward—Paper NDAs and ANDAs for Post-1962 Drugs—The Pioneer Manufacturer's View. Mar., p. 129.

Rogers, Paul G.—Medical Device Law—Intent and Implementation. Jan., p. 4.

The Role of Corporate Management During a Device Inspection. Oct., p. 536.

The Role of the Lawyer in Agency Decision-Making. Oct., p. 510.

Ronk, Richard J.—Cyclic Review—Looking Backward or Looking Forward? Apr., p. 156.

Ruggieri, Nicholas L.—Generic Drug Substitution and the FDA List of Approved Drug Products. Nov., p. 556.

Rulis, Alan M.—Cyclic Review—Looking Backward or Looking Forward? Apr., p. 156.

S

Safir, Peter O.—FDA Regulations and Product Liability. Sept., p. 478.

Schaefer, John F.—Inspection Policy. Sept., p. 493.

Schindler, Jerome R.—A Common Sense Approach to Common or Usual Names, if Any There Be. June, p. 284.

Science Court
Scientists and Lawyers in the Legal Process. Jan., p. 9.

Scientists and Lawyers in the Legal Process. Jan., p. 9.

Self-Medication
Does Self-Medication Have a Role in Our Society? Dec., p. 604.

Does Self-Medication Have a Role in Our Society? Dec., p. 604.

Standard, Kenneth G.—Risk Assessment and Cosmetic Regulation: The Outlook. Apr., p. 203.

Stanley, George R.—Use of Foreign Data in a New Drug Application. June, p. 340.

Sterilization Compliance
FDA's Sterilization Compliance Program. Sept., p. 460.

Sturniolo, E. J.—FDA's Sterilization Compliance Program. Sept., p. 460.

Summary Judgment
Use of Summary Judgment by the FDA to Avoid Formal Adjudication: In the Public Interest? Aug., p. 396.

T

Trinker, Deborah Shur—Perspectives on the FDA Status of Drug Products Manufactured by the Recombinant DNA Technique. Oct., p. 517.

U

Use of Foreign Data in a New Drug Application. June, p. 340.

Use of Summary Judgment by the FDA to Avoid Formal Adjudication: In the Public Interest? Aug., p. 396.

V

Vodra, William W.—Litigating an "Old Drug"/"New Drug" Case: Victory Lies Outside the Courtroom. Apr., p. 191.

W

Walsh, Charles J.—Presenting and Challenging Expert Witnesses in Cases Involving the New Drug—Old Drug Issue. July, p. 372.

Y

Yingling, Gary L.—Does Self-Medication Have a Role in Our Society? Dec., p. 604.